Loading clinical trials...
Loading clinical trials...
Pharmacokinetics of Anidulafungin Given Intravenously as Antifungal Prophylaxis to Recipients of an Allogeneic Haematopoietic Stem Cell Transplant Following Myeloablative Chemotherapy or Patients Receiving Intensive Chemotherapy for AML-MDS
Conditions
Interventions
anidulafungin 200 mg q48h
anidulafungin 300 mg q72h
Locations
1
Netherlands
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands
Start Date
November 1, 2010
Primary Completion Date
January 1, 2013
Completion Date
January 1, 2013
Last Updated
December 8, 2020
NCT00106925
NCT06311227
NCT06285890
NCT07388563
NCT07350863
NCT06220162
Lead Sponsor
Radboud University Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions